Literature DB >> 10947205

Reduction of large neutral amino acid concentrations in plasma and CSF of patients with maple syrup urine disease during crises.

M Wajner1, D M Coelho, A G Barschak, P R Araújo, R F Pires, F L Lulhier, C R Vargas.   

Abstract

Neurological dysfunction is common in patients with maple syrup urine disease (MSUD). However, the mechanisms underlying the neuropathology of this disorder are poorly understood. We determined the concentrations of all amino acids in plasma of patients with MSUD during crises (with severe CNS symptoms) and after recovery in the hope of detecting possible alterations of these levels during metabolic decompensation. Blood samples obtained from 11 children with MSUD aged 1 month to 7 years and from 10 age-matched controls (5 months to 6 years) with no evidence of metabolic disease were examined for their amino acid content by high-performance liquid chromatography. We observed that leucine, isoleucine and valine concentrations were respectively 30, 9 and 3 times higher than normal values, whereas the concentrations of the large neutral amino acids (LNAA) phenylalanine, tyrosine, tryptophan and methionine were significantly lower during metabolic decompensation as compared to the controls. In addition, concentrations of leucine, but not of valine or isoleucine, were inversely related to the LNAA concentrations in plasma. The concentrations of these amino acids in plasma returned to normal values when patients were clinically well. CSF amino acid concentrations also showed decreased amounts of LNAA and increased concentrations of branched-chain amino acids. It is possible that the decrease in plasma concentrations of LNAA may lead to a deficit of these essential amino acids in the brain as well as of their products such as proteins and neurotransmitters, a fact that might be related to the neurological dysfunction of MSUD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10947205     DOI: 10.1023/a:1005668431926

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

1.  Inhibition of brain glutamic acid decarboxylase by phenylalanine, valine, and leucine derivatives: a suggestion concerning the etiology of the neurological defect in phenylketonuria and branched-chain ketonuria.

Authors:  R E TASHIAN
Journal:  Metabolism       Date:  1961-05       Impact factor: 8.694

2.  Evidence for inhibition of exodus of small neutral amino acids from non-brain tissues in hyperphenylalaninaemic rats.

Authors:  C de Cespedes; J G Thoene; K Lowler; H N Christensen
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

3.  Where do the depleted plasma amino acids go in phenylketonuria?

Authors:  H N Christensen
Journal:  Biochem J       Date:  1986-06-15       Impact factor: 3.857

4.  Hypoglycemia and maple syrup urine disease: defective gluconeogenesis.

Authors:  M W Haymond; I E Karl; R D Feigin; D DeVivo; A S Pagliara
Journal:  Pediatr Res       Date:  1973-05       Impact factor: 3.756

5.  The influence of high phenylalanine and tyrosine on the concentrations of essential amino acids in brain.

Authors:  C M McKean; D E Boggs; N A Peterson
Journal:  J Neurochem       Date:  1968-03       Impact factor: 5.372

6.  Inhibition of brain protein synthesis: an approach to the biochemical basis of neurological dysfunction in the amino-acidurias.

Authors:  S H Appel
Journal:  Trans N Y Acad Sci       Date:  1966-11

7.  Neutral amino acid transport into rat skeletal muscle: competition, adaptive regulation, and effects of insulin.

Authors:  A R Tovar; J K Tews; N Torres; A E Harper
Journal:  Metabolism       Date:  1991-04       Impact factor: 8.694

Review 8.  Comparative aspects of the apparent Michaelis constant for neutral amino acid transport in several animal tissues.

Authors:  J Lerner; D L Larimore
Journal:  Comp Biochem Physiol B       Date:  1986

9.  Brain uptake of 11C-methionine in phenylketonuria.

Authors:  D Comar; J M Saudubray; A Duthilleul; J Delforge; M Maziere; G Berger; C Charpentier; A Todd-Pokropek
Journal:  Eur J Pediatr       Date:  1981-03       Impact factor: 3.183

10.  Inhibition of neutral amino acid transport across the human blood-brain barrier by phenylalanine.

Authors:  B L Shulkin; A L Betz; R A Koeppe; B W Agranoff
Journal:  J Neurochem       Date:  1995-03       Impact factor: 5.372

View more
  21 in total

1.  Creatine and antioxidant treatment prevent the inhibition of creatine kinase activity and the morphological alterations of C6 glioma cells induced by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.

Authors:  Cláudia Funchal; Patrícia Fernanda Schuck; André Quincozes Dos Santos; Maria Caroline Jacques-Silva; Carmem Gottfried; Regina Pessoa-Pureur; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2006-02       Impact factor: 5.046

2.  Chronic Treatment with a Clinically Relevant Dose of Methylphenidate Increases Glutamate Levels in Cerebrospinal Fluid and Impairs Glutamatergic Homeostasis in Prefrontal Cortex of Juvenile Rats.

Authors:  Felipe Schmitz; Paula Pierozan; André F Rodrigues; Helena Biasibetti; Daniella M Coelho; Ben Hur Mussulini; Mery S L Pereira; Mariana M Parisi; Florencia Barbé-Tuana; Diogo L de Oliveira; Carmen R Vargas; Angela T S Wyse
Journal:  Mol Neurobiol       Date:  2015-05-24       Impact factor: 5.590

3.  Morphological alterations and cell death provoked by the branched-chain alpha-amino acids accumulating in maple syrup urine disease in astrocytes from rat cerebral cortex.

Authors:  Cláudia Funchal; Carmem Gottfried; Lúcia Maria Vieira de Almeida; André Quincozes dos Santos; Moacir Wajner; Regina Pessoa-Pureur
Journal:  Cell Mol Neurobiol       Date:  2005-08       Impact factor: 5.046

4.  Biochemical and anaplerotic applications of in vitro models of propionic acidemia and methylmalonic acidemia using patient-derived primary hepatocytes.

Authors:  M Sol Collado; Allison J Armstrong; Matthew Olson; Stephen A Hoang; Nathan Day; Marshall Summar; Kimberly A Chapman; John Reardon; Robert A Figler; Brian R Wamhoff
Journal:  Mol Genet Metab       Date:  2020-05-11       Impact factor: 4.797

5.  The intra-hippocampal leucine administration impairs memory consolidation and LTP generation in rats.

Authors:  Viviane Glaser; Valeria P Carlini; Laura Gabach; Marisa Ghersi; Susana Rubiales de Barioglio; Oscar A Ramirez; Mariela F Perez; Alexandra Latini
Journal:  Cell Mol Neurobiol       Date:  2010-06-26       Impact factor: 5.046

6.  Serum Markers of Neurodegeneration in Maple Syrup Urine Disease.

Authors:  Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuk; Gustavo C Ferreira; Joao Seda Neto; Tatiana Amorin; Ida Vanessa D Schwartz; Emilio L Streck
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

7.  Behavioral responses in rats submitted to chronic administration of branched-chain amino acids.

Authors:  Giselli Scaini; Gabriela C Jeremias; Camila B Furlanetto; Diogo Dominguini; Clarissa M Comim; João Quevedo; Patrícia F Schuck; Gustavo C Ferreira; Emilio L Streck
Journal:  JIMD Rep       Date:  2013-11-09

8.  Oxidative stress in plasma from maple syrup urine disease patients during treatment.

Authors:  Alethéa G Barschak; Angela Sitta; Marion Deon; Amanda T Barden; Carlos S Dutra-Filho; Moacir Wajner; Carmen R Vargas
Journal:  Metab Brain Dis       Date:  2007-11-17       Impact factor: 3.584

Review 9.  Animal models of maple syrup urine disease.

Authors:  K J Skvorak
Journal:  J Inherit Metab Dis       Date:  2009-03-09       Impact factor: 4.982

10.  Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease.

Authors:  William J Zinnanti; Jelena Lazovic; Kathleen Griffin; Kristen J Skvorak; Harbhajan S Paul; Gregg E Homanics; Maria C Bewley; Keith C Cheng; Kathryn F Lanoue; John M Flanagan
Journal:  Brain       Date:  2009-03-17       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.